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Purpose: The cytochrome p450 family 1 subfamily B (CYP1B1) gene is a well known cause of autosomal recessive
primary congenital glaucoma. It has also been postulated as a modifier of disease severity in primary open angle glaucoma
(POAG), particularly in juvenile onset families. However, the role of common variation in the gene in relation to POAG
has not been thoroughly explored.
Methods: Seven tag single nucleotide polymorphisms (SNPs), including two coding variants (L432V and N543S), were
genotyped in 860 POAG cases and 898 examined normal controls. Each SNP and haplotype was assessed for association
with disease. In addition, a subset of 396 severe cases and 452 elderly controls were analyzed separately.
Results: There was no association of any individual SNP in the full data set. Two SNPs (rs162562 and rs10916) were
nominally associated under a dominant model in the severe cases (p<0.05). A common haplotype (AGCAGCC) was also
found to be nominally associated in both the full data set (p=0.048, OR [95%CI]=0.83 [0.69–0.90]) and more significantly
in the severe cases (p=0.004, OR [95%CI]=0.68 [0.52–0.89]) which survives correction for multiple testing.
Conclusions: Although no major effect of common variation at the CYP1B1 locus on POAG was found, there could be
an effect of SNPs tagged by rs162562 and represented on the AGCAGCC haplotype.
The cytochrome p450 family 1 subfamily B (CYP1B1)
is a member of the CYP450 superfamily. While its exact
function and effect on cells is not clear, the gene is inducible
by dioxins and has several endogenous substrates including
17β-estradiol, retinoic acid, and melatonin as well as many
exongenous substrates [1]. It was first recognized as a cause
of  primary  congenital  glaucoma  (PCG)  following  linkage
mapping [2] and candidate gene screening [3] in a panel of 17
Turkish families with recessive PCG. This finding has since
been replicated in many ethnic groups with over 80 mutations
now  reported  from  many  different  populations  [1,4,5].  In
many  cases,  compound  heterozygosity  is  observed  as  the
cause  of  recessive  disease.  The  proportion  of  PCG  cases
accounted  for  by  CYP1B1  mutations  varies  significantly
between ethnic groups, from around 20% in Australia and
Japan to nearly 100% in Saudi Arabia and Slovakian Gypsies
[4].
Primary  Open  Angle  Glaucoma  (POAG)  is  the  most
prevalent form of glaucoma and leads to significant levels of
irreversible  blindness  worldwide.  The  genetics  of  this
complex trait are not well understood, although many loci and
several  genes  have  been  reported  [6].  The  most  common
known  genetic  cause  of  POAG  is  the  myocilin  gene
(MYOC). Mutations in this gene account for 2%–4% of POAG
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in Caucasians [7] and up to 36% in juvenile onset (JOAG)
families [8]. CYP1B1 mutations have also been identified in
JOAG and POAG patients. Melki et al. [9] reported compound
heterozygotes in three French families containing patients
with PCG as well as JOAG. Acharya et al. [10] reported nine
individuals from India (4 JOAG and 5 POAG) with single
heterozygous mutations in CYP1B1 and Kumar et al. [11]
reported  four  mutations  in  27  Indian  POAG  patients,
including two who were compound heterozygotes. Lopez-
Garrido et al. [12] presented heterozygous mutations in 10
Spanish POAG patients. CYP1B1 has also been suggested as
a modifier of POAG in carriers of MYOC mutations [13]. A
common polymorphism was associated with cupping of the
optic disc, which may be relevant to POAG [14] although
other studies found no association of CYP1B1 mutations with
disc changes in POAG [15].
Although several studies have reported rare variants in
the CYP1B1 gene in glaucoma patients that were not detected
in controls [10-15], no large scale re-sequencing of normal
population has been performed to determine the spectrum of
rare  variants  in  this  gene.  There  are  75  reported  coding
variants in dbSNP, of which 45 are non-synonymous, 11 are
insertions or deletions, and 4 are truncating mutations. While
the  majority  have  not  yet  been  thoroughly  validated  as
common polymorphisms, the number of reported frameshift
and non-synonymous variants suggests that CYP1B1 activity
is not compromised by most mutational events, at least in the
heterozygous state. Thus, the presence of rare variants in the
sequenced  glaucoma  patients  is  not  surprising.  The  link
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2286between  CYP1B1  and  POAG  is  therefore  currently
circumstantial. Chakrabarti et al. [15] assessed six common
polymorphisims in a small cohort of POAG and primary angle
closure glaucoma (PACG) patients as well as controls and
found no association of any haplotypes with glaucoma status.
This  study  aims  to  evaluate  the  contribution  of  common
polymorphisms in CYP1B1 to POAG.
METHODS
Patients:  Participants  were  drawn  from  the  Glaucoma
Inheritance Study in Tasmania (GIST), the Australian & New
Zealand Registry of Advanced Glaucoma (ANZRAG) and the
Blue Mountains Eye Study (BMES). The GIST and ANZRAG
includes a clinic-based recruitment of glaucoma patients. The
GIST aimed to capture all cases of glaucoma in Tasmania (an
island state of Australia) and ANZRAG aims to capture cases
of  advanced  glaucoma  Australia-wide  through
ophthalmologist referral [16,17]. In both cases, normal elderly
controls  were  ascertained  from  nursing  home  facilities  in
Launceston,  Tasmania  (for  GIST)  and  Adelaide,  South
Australia (for ANZRAG). The BMES is a population based
study of individuals aged over 50 years living in the Blue
Mountains, west of Sydney, Australia [18]. All participants,
including normal controls in all three studies were examined.
Glaucoma  was  defined  by  concordant  findings  of  typical
glaucomatous visual field defects on the Humphrey 24–2 (for
GIST and ANZRAG) or 30–2 (for BMES) test, together with
corresponding optic disc rim thinning, including an enlarged
cup-disc  ratio  (≥0.7)  or  cup-disc  ratio  asymmetry  (≥0.2)
between the two eyes. Intraocular pressure (IOP) was not
considered in the diagnostic criteria. Advanced POAG was
defined by a vertical cup:disc ratio >0.95, a best-corrected
visual acuity worse than 6/60 due to POAG, or on a reliable
Humphrey  Visual  Field  (Carl  Zeiss  Pty.  Ltd.,  Sydney,
Australia) a mean deviation of ≤-22 db or at least 10 out of 16
central squares involved with a Pattern Standard Deviation of
<0.5%. The field loss had to be due to POAG, and the less
severely  affected  eye  was  required  to  have  signs  of
glaucomatous disc damage and a glaucomatous field defect.
Clinical  exclusion  criteria  included:  i)  pseudoexfoliative
glaucoma,  ii)  pigmentary  glaucoma,  iii)  angle  closure  or
mixed mechanism glaucoma; iv) secondary glaucoma due to
aphakia, rubella, rubeosis or inflammation; v) congenital or
infantile glaucoma, juvenile glaucoma with age of onset less
than 20 years; or vi) glaucoma in the presence of a known
syndrome.
All control subjects were required to have no known
family  history  of  POAG,  as  well  as  a  normal  intraocular
pressure, optic disc and visual field. The population-based
BMES control cohort comprised the eldest subgroup of people
meeting control inclusion criteria.
SNP  selection  and  genotyping:  Using  the  tagger  program
implemented  in  Haploview  4.0  [19]  tag  single  nucleotide
polymorphisms  (SNPs)  across  the  CYP1B1  gene  were
selected  on  the  basis  of  linkage  disequilibrium  patterns
observed in the Caucasian (CEU) samples genotyped as part
of the International HapMap Project [20]. Only SNPs with
minor  allele  frequency  greater  than  5%  in  HapMap  were
considered.  Two  coding  SNPs  (rs1056836  and  rs1800440
coding L432V and N453S respectively) and four 3′UTR SNPs
(rs162549, rs2855358, rs10916, and rs162562) were force
included to capture as much coding variation as possible. In
addition,  intronic  SNPs  rs10175368  and  rs162556  were
selected. These eight tag SNPs captured all alleles with an r2
of  at  least  0.8  (mean  r2=0.96)  and  were  gentoyped  in  all
individuals using iPLEX GOLD chemsitry (Sequenom Inc.,
San  Diego,  CA)  on  an  Autoflex  Mass  Spectrometer
(Sequenom Inc.) at the Australian Genome Research Facility,
Brisbane,  Australia.  The  3′UTR  SNP  rs2855658  failed
genotyping and was removed from the analysis. This SNP did
not tag any other HapMap SNPs.
Statistical analysis: All analyses were conducted using the
statistical  genetics  software  packages  Plink  [21]  and
Haploview [19]. Hardy Wienberg equilibrium was assessed
in all samples and in controls separately. Association was
tested under the five genetic models implemented in Plink.
These  models  are  the  allelic  test  (allele1  versus  allele2),
genotypic (11 versus 12 versus 22), dominant (11 and 12
versus 22), recessive (11 versus 12 and 22) and the Cochrane-
Armitage  Trend  test.  Association  of  common  haplotypes
(>1%  frequency)  was  also  assessed  in  Plink  using  the
conditional haplotype test. All analyses were conducted in the
full data set as well as a sub-set of cases with severe disease
(from GIST and ANZRAG) compared to elderly (>81 years
TABLE 1. DEMOGRAPHICS BY RECRUITMENT CENTER.
 
N Sex (% female) Age (mean ±SD)
Cohort Cases Controls Cases Controls p-value Cases Controls p-value
Full Sample 860 897 0.52 0.53 0.82 74.8 80.5 <0.001
Severe Sample 396 452 0.53 0.53 0.98 77.0 85.3 <0.001
ANZRAG 230 285 0.47 0.55 0.05 82.4 76.0 <0.001
GIST 476 101 0.60 0.68 0.16 73.3 86.3 <0.001
BMES 154 511 0.36 0.48 0.01 77.7 81.1 <0.001
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2288of age) examined controls. Power calculations [22] revealed
that, assuming a prevalence of 3% in this population, for a
sample of this size (860 cases versus 898 controls) under an
additive  model  we  had  99%  power  to  detect  a  genotype
relative risk of 1.1 for an allele frequency of 0.4 at α=0.007
(allowing  for  multiple  testing  of  7  SNPs).  For  an  allele
frequency of 0.2, the power is 71% for a relative risk of 1.1,
92% for 1.2, and 98% for 1.3.
RESULTS
In  total,  860  cases  and  897  examined,  normal,  unrelated
controls were available. Sex and age distribution for the full
cohort and each sub-cohort are given in Table 1. Overall, the
age of cases is significantly less than the controls, although in
the ANZRAG cohort the cases are slightly older. There were
no differences in the proportion of each cohort that is female.
All seven SNPs were in Hardy–Weinberg equilibrium.
Allele  and  genotype  frequencies  by  glaucoma  status  are
shown in Table 2. Linkage disequilibrium across the region is
high with all seven SNPs falling into a single block, although
the correlation between SNPs rs162556 and rs10175368 is
low  (Figure  1),  consistent  with  values  observed  in  the
HapMap data set. Thus using the block definition of Gabriel
et al. [23] there are two haplotype blocks as shown in Figure
1.
Single SNP association analysis was conducted for five
genetic models in Plink. No SNP was associated under the
allelic test, nor in any of the other genetic models (Table 3).
When the analysis was restricted to severe cases and elderly
controls (≥81 years) only, SNPs rs162562 and rs10916 were
nominally associated (p<0.05); however, these results do not
survive  correction  for  the  number  of  SNPs  assessed.  The
associations  were  also  nominally  significant  under  the
recessive  model  and  trend  test.  In  addition,  a  logistic
regression adjusted for age and sex was conducted. Nominally
significant results at the same two SNPs were observed in the
severe cohort, but do not survive multiple testing correction
(Table 3).
Haplotype analysis was conducted in Plink. No overall
association  between  the  CYP1B1  locus  and  POAG  was
detected in either the full sample (p=0.140) nor the severe
cases and elderly controls (p=0.189); however, one specific
haplotype of the seven SNPs (AGCAGCC) was nominally
Figure  1.  Linkage  disequilibrium
pattern between tag SNPs typed in the
CYP1B1 gene. R2 values are given in the
intersecting boxes, with darker colors
indicating  stronger  linkage
disequilibrium.  The  position  of  each
SNP relative to the gene is indicated.
Figure generated in Haploview [19].
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2289associated in both data sets (Table 4). This is a relatively
common  haplotype  that  is  slightly  under-represented  in
POAG cases, particularly severe cases. The association does
survive correction for multiple testing of the seven common
haplotypes in the severe cases (corrected p-value=0.028). The
associated haplotype is the most common haplotype to carry
a C at SNP rs162562, which was nominally significant in the
single SNP analysis of the severe cases. This allele is observed
in only one other haplotype (AGCAGTG) which only differs
from the associated haplotype at the 6th SNP (rs162556), but
is rarer and is not associated with POAG.
DISCUSSION
The  association  of  the  CYP1B1  gene  with  PCG  is  well
understood  in  populations  world-wide,  although  the
mechanism of disease is not. The gene is also associated with
JOAG and may interact with the MYOC gene to cause the early
onset  observed  in  JOAG  families.  However,  the  role  of
CYP1B1 in later onset POAG is unclear. The majority of
studies to date have sequenced the coding region of the gene
in a small cohort of POAG patients and most have identified
missense mutations not observed in a control cohort. This
approach has identified many apparent mutations that may
contribute to the risk of POAG in rare cases, but does not
provide evidence for a contribution of this locus to most (or
even a significant proportion) of POAG cases. In addition,
there are many reported missense, frameshift and truncating
variants of this gene in non-POAG individuals, many of which
have  not  been  reported  in  the  POAG  cohorts,  making
interpretation  of  the  published  data  in  relation  to  POAG
susceptibility difficult.
The present CYP1B1 study is the largest cohort of POAG
patients examined to date (n=860) and we were well powered
to identify common genetic variants at the level of relative risk
of 1.1 or 1.2. In addition, all controls (n=898) are at least 50
years of age and have been thoroughly examined for glaucoma
phenotypes. We have taken a tag SNP approach to assess the
role of common variation throughout the CYP1B1 locus for
an association with POAG in both a general POAG cohort as
well as a cohort of severe (typically slightly younger onset)
cases  compared  to  elderly  (>81  years)  examined  normal
controls. These data do not provide evidence for a substantial
role of this locus in POAG, although one haplotype may be
protective  for  severe  glaucoma  .  The  odds  ratio  for  the
nominally associated haplotype is 0.68 when compared to all
other common haplotypes. Power calculations [22] revealed
that for a sample of this size (860 cases versus 898 controls)
under  an  additive  model  we  had  88%  power  to  detect  a
genotype relative risk of 0.68 (or 1.47) for an allele frequency
of  0.16  at  α=0.007  (allowing  for  multiple  testing  of  7
TABLE 3. P-VALUE FOR ASSOCIATION OF EACH SNP WITH POAG.
All cases (n=860 versus all controls (n=897)      
SNP Allelic Genotypic Dominant Trend Recessive Adjusted*
rs162549 0.637 0.725 0.853 0.643 0.424 0.822
rs10916 0.140 0.325 0.217 0.145 0.238 0.054
rs162562 0.112 0.268 0.185 0.116 0.120 0.040
rs1800440 0.617 0.614 0.848 0.620 0.325 0.259
rs1056836 0.976 0.711 0.674 0.977 0.600 0.430
rs162556 0.071 0.117 0.307 0.066 0.042 0.078
rs10175368 0.422 0.716 0.490 0.420 0.533 0.223
Severe cases (n=396) versus Elderly controls (n=452)      
SNP Allelic Genotypic Dominant Trend Recessive Adjusted*
rs162549 0.686 0.826 0.585 0.695 0.923 0.824
rs10916 0.018 0.060 0.019 0.020 0.280 0.016
rs162562 0.019 0.063 0.020 0.022 0.299 0.017
rs1800440 0.381 0.687 0.413 0.386 0.612 0.531
rs1056836 0.150 0.354 0.287 0.156 0.201 0.040
rs162556 0.112 0.040 0.772 0.108 0.013 0.129
rs10175368 0.307 0.502 0.481 0.309 0.268 0.091
         Results are presented for 5 genetic models and the adjusted model for the full sample and the sample restricted to severe cases
         and elderly controls. Nominally significant p-values are highlighted in bold. The asterisk indicates p-values adjusted for age
         and sex in a logistic regression.
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2291haplotypes). Thus we are adequately powered to detect the
effect size observed in this study.
The use of tag SNPs in case-control association studies
is ideally suited to testing hypotheses of common variation
causing a common disease. It will not detect individual rare
variants occurring on multiple genetic backgrounds. Thus,
this study does not rule out a role for CYP1B1 in POAG, but
does indicate that common variation in the gene (including
common coding SNPs L432V and N453S) is not associated
with POAG in general, but may be associated with severe
POAG in a Caucasian population.
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